Brokerages predict that Denali Therapeutics Inc (NASDAQ:DNLI) will announce $10.86 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Denali Therapeutics’ earnings. The highest sales estimate is $23.50 million and the lowest is $1.20 million. Denali Therapeutics reported sales of $1.20 million during the same quarter last year, which indicates a positive year-over-year growth rate of 805%. The firm is scheduled to report its next earnings report on Thursday, November 14th.
On average, analysts expect that Denali Therapeutics will report full year sales of $33.72 million for the current fiscal year, with estimates ranging from $10.79 million to $83.79 million. For the next year, analysts anticipate that the business will post sales of $54.60 million, with estimates ranging from $10.79 million to $175.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Denali Therapeutics.
Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.15). The company had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.52 million. Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%.
DNLI has been the subject of several research reports. TheStreet cut shares of Denali Therapeutics from a “c-” rating to a “d” rating in a research report on Thursday, June 13th. ValuEngine cut shares of Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 2nd. Zacks Investment Research upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 27th. HC Wainwright restated a “buy” rating on shares of Denali Therapeutics in a research report on Thursday, August 8th. Finally, Nomura initiated coverage on shares of Denali Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $35.00 price objective for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Denali Therapeutics presently has an average rating of “Buy” and an average target price of $27.25.
In other news, COO Alexander O. Schuth sold 7,500 shares of Denali Therapeutics stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $18.81, for a total transaction of $141,075.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Ryan J. Watts sold 8,581 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $18.05, for a total transaction of $154,887.05. Following the sale, the chief executive officer now owns 12,505 shares of the company’s stock, valued at approximately $225,715.25. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,581 shares of company stock valued at $432,162. 21.20% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the company. TD Asset Management Inc. grew its position in shares of Denali Therapeutics by 2.2% during the 1st quarter. TD Asset Management Inc. now owns 23,400 shares of the company’s stock worth $543,000 after buying an additional 500 shares during the period. Virtus ETF Advisers LLC grew its position in shares of Denali Therapeutics by 7.9% during the 2nd quarter. Virtus ETF Advisers LLC now owns 14,246 shares of the company’s stock worth $296,000 after buying an additional 1,045 shares during the period. JPMorgan Chase & Co. grew its position in shares of Denali Therapeutics by 19.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,170 shares of the company’s stock worth $271,000 after buying an additional 2,101 shares during the period. Swiss National Bank grew its position in shares of Denali Therapeutics by 2.0% during the 2nd quarter. Swiss National Bank now owns 114,800 shares of the company’s stock worth $2,383,000 after buying an additional 2,300 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its position in shares of Denali Therapeutics by 19.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 20,555 shares of the company’s stock worth $427,000 after buying an additional 3,330 shares during the period. Institutional investors own 73.91% of the company’s stock.
DNLI traded up $0.39 during midday trading on Thursday, hitting $15.20. The company had a trading volume of 192,494 shares, compared to its average volume of 352,003. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.66 and a current ratio of 10.65. The company has a market capitalization of $1.46 billion, a PE ratio of -38.97 and a beta of 2.15. Denali Therapeutics has a twelve month low of $13.78 and a twelve month high of $28.86. The firm’s 50-day simple moving average is $17.38 and its 200-day simple moving average is $20.51.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Featured Article: CD Ladder
Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.